MX2019012144A - Arn para tratamiento de enfermedades autoinmunitarias. - Google Patents

Arn para tratamiento de enfermedades autoinmunitarias.

Info

Publication number
MX2019012144A
MX2019012144A MX2019012144A MX2019012144A MX2019012144A MX 2019012144 A MX2019012144 A MX 2019012144A MX 2019012144 A MX2019012144 A MX 2019012144A MX 2019012144 A MX2019012144 A MX 2019012144A MX 2019012144 A MX2019012144 A MX 2019012144A
Authority
MX
Mexico
Prior art keywords
rna
treatment
autoimmune diseases
autoantigen
development
Prior art date
Application number
MX2019012144A
Other languages
English (en)
Inventor
Kreiter Sebastian
Diken Mustafa
Mareen Kranz Lena
Sahin Ugur
Krienke Christina
PETSCHENKA Jutta
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of MX2019012144A publication Critical patent/MX2019012144A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a ARN no inmunogénico. Este ARN forma la base para el desarrollo de agentes terapéuticos para inducir tolerancia hacia un autoantígeno y, por lo tanto, para el tratamiento de enfermedades autoinmunitarias.
MX2019012144A 2017-04-11 2018-04-10 Arn para tratamiento de enfermedades autoinmunitarias. MX2019012144A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2017/058651 WO2018188730A1 (en) 2017-04-11 2017-04-11 Rna for treatment of autoimmune diseases
PCT/EP2018/059188 WO2018189193A1 (en) 2017-04-11 2018-04-10 Rna for treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
MX2019012144A true MX2019012144A (es) 2019-11-21

Family

ID=58632945

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012144A MX2019012144A (es) 2017-04-11 2018-04-10 Arn para tratamiento de enfermedades autoinmunitarias.

Country Status (22)

Country Link
US (2) US11701413B2 (es)
EP (2) EP3981424A1 (es)
JP (3) JP7078641B2 (es)
KR (2) KR20190134765A (es)
CN (2) CN110719787B (es)
AU (1) AU2018253352A1 (es)
BR (1) BR112019020667A8 (es)
CA (1) CA3059505A1 (es)
CY (1) CY1124767T1 (es)
DK (1) DK3609529T3 (es)
ES (1) ES2893451T3 (es)
HR (1) HRP20211559T1 (es)
HU (1) HUE056871T2 (es)
IL (2) IL269793B (es)
LT (1) LT3609529T (es)
MX (1) MX2019012144A (es)
PL (1) PL3609529T3 (es)
PT (1) PT3609529T (es)
RS (1) RS62582B1 (es)
SG (2) SG11201909520VA (es)
SI (1) SI3609529T1 (es)
WO (2) WO2018188730A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020102172A2 (en) * 2018-11-12 2020-05-22 Translate Bio, Inc. Methods for inducing immune tolerance
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
CN115232825B (zh) * 2021-04-22 2023-09-26 中国人民解放军军事科学院军事医学研究院 一种基于1083骨架的新冠病毒疫苗
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
BR112023024116A2 (pt) 2021-05-26 2024-02-06 Imcyse Sa Métodos de tratamento ou prevenção de doenças autoimunes
AR126654A1 (es) 2021-06-29 2023-11-01 Imcyse Sa Péptidos y métodos para el tratamiento de neuromielitis óptica
CN113336862B (zh) * 2021-07-05 2022-03-01 广东省科学院动物研究所 一种抗多发性硬化的重组蛋白及其制备方法和用途
WO2023030635A1 (en) 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
CN118369335A (zh) * 2022-01-06 2024-07-19 上海吉量医药工程有限公司 N1位修饰假尿嘧啶核苷及其在mRNA合成中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030098B2 (en) * 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
AU2002952834A0 (en) * 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
ES2735531T3 (es) 2005-08-23 2019-12-19 Univ Pennsylvania ARN que contiene nucleósidos modificados y métodos de uso del mismo
US9012219B2 (en) * 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
SG181564A1 (en) * 2009-12-07 2012-07-30 Katalin Kariko Rna preparations comprising purified modified rna for reprogramming cells
WO2012154933A1 (en) * 2011-05-10 2012-11-15 The Brigham And Women's Hospital, Inc. Detecting inclusion body myositis
WO2013044419A1 (en) * 2011-09-30 2013-04-04 Beijing Advaccine Biotechnology Co., Ltd. Combined facilitator, antigen and dna vaccine for preventing and treating autoimmune diseases
EP2798064B1 (en) 2011-12-30 2016-08-31 Cellscript, Llc Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect
WO2013120498A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
CA2984125A1 (en) * 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
CN106395552B (zh) * 2015-08-03 2020-03-17 奥的斯电梯公司 无绳电梯***导轨组件
AU2016315444B2 (en) * 2015-08-28 2023-02-23 BioNTech SE Method for reducing immunogenicity of RNA
ES2900272T3 (es) * 2016-04-22 2022-03-16 BioNTech SE Métodos para proporcionar ARN monocatenario

Also Published As

Publication number Publication date
JP2022110127A (ja) 2022-07-28
IL269793B (en) 2022-04-01
JP2020516658A (ja) 2020-06-11
JP2024059794A (ja) 2024-05-01
US20230330198A1 (en) 2023-10-19
LT3609529T (lt) 2021-10-25
BR112019020667A2 (pt) 2020-05-05
RU2019135808A (ru) 2021-05-11
PL3609529T3 (pl) 2021-12-13
EP3609529A1 (en) 2020-02-19
PT3609529T (pt) 2021-10-14
SI3609529T1 (sl) 2021-11-30
SG11201909520VA (en) 2019-11-28
EP3981424A1 (en) 2022-04-13
US11701413B2 (en) 2023-07-18
JP7444924B2 (ja) 2024-03-06
DK3609529T3 (da) 2021-10-11
HUE056871T2 (hu) 2022-04-28
IL290980A (en) 2022-05-01
HRP20211559T1 (hr) 2022-01-21
ES2893451T3 (es) 2022-02-09
KR20240042138A (ko) 2024-04-01
BR112019020667A8 (pt) 2022-08-16
WO2018189193A1 (en) 2018-10-18
CY1124767T1 (el) 2022-11-25
CA3059505A1 (en) 2018-10-18
KR20190134765A (ko) 2019-12-04
CN110719787A (zh) 2020-01-21
CN110719787B (zh) 2024-03-15
CN118161602A (zh) 2024-06-11
IL269793A (en) 2019-11-28
RS62582B1 (sr) 2021-12-31
AU2018253352A1 (en) 2019-10-17
JP7078641B2 (ja) 2022-05-31
SG10202111163VA (en) 2021-11-29
WO2018188730A1 (en) 2018-10-18
US20200061166A1 (en) 2020-02-27
RU2019135808A3 (es) 2021-08-10
EP3609529B1 (en) 2021-09-08

Similar Documents

Publication Publication Date Title
MX2019012144A (es) Arn para tratamiento de enfermedades autoinmunitarias.
IL272410A (en) Cytokine conjugates for the treatment of autoimmune diseases
PH12019501959A1 (en) Therapeutic rna
CA193736S (en) Skin massager
MX2023010042A (es) Polinucleotidos moduladores.
MX2020003425A (es) Tratamiento de trastornos inflamatorios.
MX2018012880A (es) Metodos para proporcionar arn de hebra sencilla.
MX2018008515A (es) Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones inmunitarias.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
GEP20217252B (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
PH12019500494A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
EA201991997A1 (ru) Комбинированная терапия
IL269895B2 (en) Coversin for the treatment of autoimmune blistering diseases
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX2020004662A (es) Ajuste planificado del contorno mediante especificaciones correspondientes.
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
MX2018007408A (es) Uso de adyuvantes para la prevencion y/o el tratamiento de enfermedades autoinmunes.
MX2019000600A (es) Agente estimulador del receptor 5-hidroxitriptamina 1b para reparación de piel y/o cabello.
MX2017013879A (es) Composiciones que comprenden anakinra.